Excellent survival benefit achieved in patients with advanced-stage non-small cell lung cancer harboring the epidermal growth factor receptor-G719X mutation treated by afatinib: the real-world data from a multicenter study in Vietnam
Therapeutic Advances in Respiratory Disease · 2025
DOI: 10.1177/17534666251341747 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Therapeutic Advances in Respiratory Disease, 2025. Verfasst von Van Luan Pham und 19 weiteren Autor:innen. Beteiligte Einrichtung: Military Central Hospital 108, Hanoi, Vietnam. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Afatinib, Lung Neoplasms, Mutation. Die Arbeit nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
Afatinib is indicated for patients with advanced-stage non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations, including uncommon mutations. However, the differences in survival benefits between patients with different types of EGFR mutations remain unclear.
Objectives
This study aimed to compare the effectiveness of afatinib treatment in patients harboring the EGFR-G719X mutation with that in patients carrying other uncommon EGFR mutations.
Design
This was a retrospective study.
Methods
Ninety-two patients with locally advanced and metastatic NSCLC, of whom 49 patients with EGFR-G719X mutations that were both single and compound, and 43 patients harbored other uncommon EGFR mutations, who were treated with afatinib as first-line treatment. The patients were followed up and evaluated every 3 months or when there were symptoms of progressive disease. The endpoints were the objective response rate (ORR), time-to-treatment failure (TTF), and overall survival (OS).
Results
The average ages of patients with the EGFR-G719X and uncommon EGFR mutations were 62.7 years and 63.1 years, respectively. There were no significant differences in sex or smoking history between the two groups. In total, 28.6% of patients with the G719X mutation and 23.3% of patients with other mutations had brain metastases. The ORR of patients with the G719X mutation was 79.6%, which was 10% higher than that of patients with other EGFR mutations. Patients harboring the EGFR-G719X mutation had median TTF and median OS periods of 19.3 months and 31.4 months, respectively, which were significantly higher than those of patients carrying other mutations at 11.2 months. Subgroup analysis showed that TTF and OS benefits were observed in female patients, patients without brain metastasis, and patients with good performance status who harbored the G719X mutation.
Conclusion
Patients with the EGFR-G719X mutation achieve significantly better TTF and OS benefits than those with other uncommon EGFR mutations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Military Central Hospital 108, Hanoi, Vietnam.
- College of Health Sciences, VinUniversity, Vietnam.
- Hanoi Medical University, Hanoi, Vietnam.
- Bach Mai Hospital, Giai Phong, Hanoi, Vietnam.
- University of Medicine and Pharmacy, Vietnam National University, Hanoi, Vietnam.
- Vietnam National Cancer Hospital, Hanoi, Vietnam.
ORCID-Profile: Van Luan Pham, Cam Phuong Pham, Dinh Thy Hao Vuong, Hung Kien Do, Ha Thanh Vu, Van Thai Pham, Hoang Gia Nguyen, Cong Minh Truong
Zitieren
APA
Pham, V. L., Pham, C. P., Nguyen, T. T. H., Nguyen, T. K., Nguyen, M. H., Hoang, T. A. T., Le, T. A., Vuong, D. T. H., Nguyen, D. N. T., Dang, V. K., Nguyen, T. O., Do, H. K., Vu, H. T., Nguyen, T. T. H., Pham, V. T., Trinh, L. H., Nguyen, H. G., Truong, C. M., Pham, T. M. C., & Nguyen, T. B. P. (2025). Excellent survival benefit achieved in patients with advanced-stage non-small cell lung cancer harboring the epidermal growth factor receptor-G719X mutation treated by afatinib: the real-world data from a multicenter study in Vietnam. Therapeutic Advances in Respiratory Disease. https://doi.org/10.1177/17534666251341747
Vancouver
Pham VL, Pham CP, Nguyen TTH, Nguyen TK, Nguyen MH, Hoang TAT, et al. Excellent survival benefit achieved in patients with advanced-stage non-small cell lung cancer harboring the epidermal growth factor receptor-G719X mutation treated by afatinib: the real-world data from a multicenter study in Vietnam. Therapeutic Advances in Respiratory Disease. 2025. doi:10.1177/17534666251341747
BibTeX
@article{Pham2025,
author = {Pham, Van Luan and Pham, Cam Phuong and Nguyen, Thi Thai Hoa and Nguyen, Tuan Khoi and Nguyen, Minh Hai and Hoang, Thi Anh Thu and Le, Tuan Anh and Vuong, Dinh Thy Hao and Nguyen, Dac Nhan Tam and Dang, Van Khiem and Nguyen, Thi Oanh and Do, Hung Kien and Vu, Ha Thanh and Nguyen, Thi Thuy Hang and Pham, Van Thai and Trinh, Le Huy and Nguyen, Hoang Gia and Truong, Cong Minh and Pham, Tran Minh Chau and Nguyen, Thi Bich Phuong},
title = {Excellent survival benefit achieved in patients with advanced-stage non-small cell lung cancer harboring the epidermal growth factor receptor-G719X mutation treated by afatinib: the real-world data from a multicenter study in Vietnam},
journal = {Therapeutic Advances in Respiratory Disease},
year = {2025},
doi = {10.1177/17534666251341747}
}
EUVIMED